Approved Treatments


Givlaari (givosiran) was approved by the U.S. Food and Drug Administration 2019 to treat adults with acute hepatic porphyria (AHP). The therapy is given as an under-the-skin injection and is designed to lower the risk of severe AHP attacks and ease symptoms.

Learn more


Panhematin (hemin for injection) is used to treat acute intermittent porphyria related to the menstrual cycle in women when carbohydrate therapy is ineffective. Given as an infusion into the vein, it works by supplying the heme the body is unable to make.

Learn more